Results 211 to 220 of about 29,136 (254)

Long-Term Durability and Dynamics of Anti-S-RBD IgG Response in Healthcare Workers: A Comparative Analysis of Homologous and Heterologous SARS-CoV-2 Vaccination Schedules in a 1-Year Serial Cross-Sectional Study. [PDF]

Med Sci Monit
Demirel Ç, Kibar F, Dağlıoğlu G, Çetiner S, Candevir A, İnal AS, Yücel Karakaya SP, Görüroğlu Öztürk Ö, Gümüş HH, İnal TC.   +9 more
europepmc   +1 more source

Shigella Effector VirA Suppresses Plant Immunity by Compromising PRA1.F3‐Dependent Accumulation of FLS2 at the Plasma Membrane

Plant, Cell &Environment, Volume 49, Issue 8, Page 5267-5282, August 2026.
ABSTRACT Surface immune receptors such as flagellin‐sensitive 2 (FLS2) are critical for plant defence, and their accumulation at the plasma membrane is tightly controlled by the endomembrane system. Here, we identify the Arabidopsis thaliana prenylated Rab acceptor PRA1.F3 as a positive regulator required for efficient accumulation of FLS2 at the ...
Sung Hee Jo, Sukyoung Jung, Myoung Hui Lee, Inhwan Hwang, Jeong Mee Park   +4 more
wiley   +1 more source

Effectiveness of heterologous mRNA vaccine boosters during an Omicron wave of COVID-19: a cross-sectional study in Macao (China). [PDF]

J Thorac Dis
Zhang J, Wang B, Lau E, Zeng Z, He W, Chen CLP, Chang C, Yang Z, Tong KL, Zhong N, Hon C.   +10 more
europepmc   +1 more source

Life Course Malaria Exposure and SARS‐CoV‐2 Seroepidemiology in Ugandan Adolescents: A Longitudinal Study Nested in a Birth Cohort

Tropical Medicine &International Health, Volume 31, Issue 8, Page 1012-1027, August 2026.
ABSTRACT Background COVID‐19 has had major global health impacts, yet reported morbidity and mortality have been lower in Africa despite serological evidence of widespread infection. Malaria has been proposed as a potential modifier of susceptibility to and outcomes of SARS‐CoV‐2 infection.
Ludoviko Zirimenya, Doreen Nayebare, Claire Baine, Jacent Nassuuna, Milly Namutebi, Christopher Zziwa, Denis Nsubuga, Fred Kiwudhu, Florence Akello, Josephine Tumusiime, Gloria Oduru, Grace Kabami, Hellen Akurut, Rachel Nakyesige, Agnes Natukunda, Anne Wajja, Lawrence Lubyayi, Simon Kimuda, Gyaviira Nkurunungi, Jennifer Serwanga, Katie J. Doores, Emily L. Webb, Alison M. Elliott   +22 more
wiley   +1 more source

Absence of autoantibodies linked to cancer and autoimmune disorders 26 weeks after BNT162b2 boosting in CoronaVac- primed individuals. [PDF]

Hum Vaccin Immunother
Mat Yassim AS, Mohd Hisham AA, Mohd Rosdan BS, Tan TM, Anuar ND, Mohamed Hashim EK, Norazmi MN.   +6 more
europepmc   +1 more source

Enhancing tuberculosis vaccine efficacy with a heterologous mRNA-ChAdOx1 prime-pull strategy targeting lung-resident memory T cells. [PDF]

Front Immunol
Korompis M, De Voss CJ, Li S, Ateere A, McShane H, Stylianou E.   +5 more
europepmc   +1 more source

Characteristics of SARS-CoV-2 Reinfection and Ancestral RBD-Blocking Antibody Levels: A Cross-Sectional Study in the Post-Zero-COVID Era from Shanghai. [PDF]

Vaccines (Basel)
Chen C, Zhu Y, Wang H, Wu F, Xie Y, Jia Q, Yang Y, Lyu J, Qu J, Wang Q, Wu F.   +10 more
europepmc   +1 more source

Engineering of Amygdalin Biosynthesis in Rice Endosperm for Pharmaceutical Production and Sitophilus oryzae Resistance

Plant Biotechnology Journal, Volume 24, Issue 8, Page 4860-4862, August 2026.
Ke Chen, Nan Chai, Shaotong Chen, Chanjuan Ye, Kangli Sun, Jie Guo, Xinqiao Zhou, Dagang Chen, Juan Liu, Yanduan Hu, Yi Zou, Rui Cao, Shu Jiang, Bocai Tang, Qinlong Zhu, Chuanguang Liu, Jiantao Tan   +16 more
wiley   +1 more source

Cross-reactive Bundibugyo antibody responses after licensed Ebola vaccines

Lhomme E, Wiedemann A, Ayouba A, Ben-Farhat S, Thaurignac G, Roy C, Beavogui AH, Doumbia S, Kieh M, Leigh B, Sow S, Migueles SA, Watson-Jones D, Yazdanpanah Y, Thiébaut R, Peeters M, Richert L, Levy Y.   +17 more
europepmc   +1 more source

Heterologous prime boost COVID 19 vaccination

Infectious Diseases Now, 2022
Heterologous prime boost vaccination is a primary vaccination with different vaccines, most often from different vaccine platforms. It combines the immunological properties of the different vaccines and thereby induces humoral, cellular and, in some cases, mucosal response.
O Launay
exaly   +3 more sources